Ryoo et al. [[16]] 2013
|
Korea
|
Prospective cohort
|
4 years
|
CP
|
>7.0 mg/dL
|
eGFR < 60
|
44/3910
|
66/14868
|
1.96 (1.28–2.99)#
|
Age, BMI, Diabetes, smoking, alcohol, blood pressure, exercise, hyperlipidaemia
|
Chang et al. [[17]] 2013
|
Taiwan
|
Prospective cohort study
|
4 years (>40 years old)
|
CP
|
>7.5 mg/dL (male) and >6.5 mg/dL (female)
|
ACR > 30
|
N.R.
|
N.R.
|
1.42 (1.27-1.59)&
|
Age, gender, BMI, Diabetes, blood pressure, Hypercholesteraemia, education
|
3.54 (2.11,5.94)#
|
Zoppini et al. [[18]] 2012
|
Italy
|
Retrospective cohort
|
5 years
|
DP
|
>7.0 mg/dL (male); >6.5 mg/dL (female)
|
eGFR < 60 or macro-albuminuria
|
47/159
|
147/1290
|
1.20 (1.03–1.57)& 2.01
|
BMI, smoking, blood pressure, albuminuria, duration of diabetes, HbA1c
|
(1.10–3.74)#
|
Sonoda et al. [[19]] 2011
|
Japan
|
Prospective cohort
|
4–5 years
|
CP
|
>7.0 mg/dL (male); >6.0 mg/dL (female)
|
eGFR < 60
|
N.R.
|
N.R.
|
1.09 (1.01–1.18)&
|
BMI, BP, LDL, HDL, smoke, eGFR
|
Kawashima et al. [[20]] 2011
|
Japan
|
Retrospective cohort
|
95.2
|
CP
|
>7.0 mg/dL
|
eGFR < 60
|
32/166
|
68/1119
|
3.99 (2.59–6.15)#
|
Age, BMI, HDL, BP, blood
|
(±66.7) months
|
Mok et al. [[21]] 2011
|
Korea
|
Severance cohort
|
6.5 years
|
CP
|
>6.6 mg/dL (male); >4.6 mg/dL (female)
|
GFR <60
|
226/3450
|
540/11489
|
2.1 (1.6–2.9) male*;
|
BMI, Diabetes, blood pressure, Hypercholesteraemia
|
1.3 (1.0-1.8) female*
|
Yamada et al. [[22]] 2011
|
Japan
|
Retrospective cohort
|
5 years
|
CP
|
>6.7 mg/dL (male); >4.8 mg/dL (female)
|
eGFR <60
|
343/3119
|
282/11280
|
1.42 (1.28–1.58) male&;
|
Age, BMI, Diabetes, smoking, alcohol, blood pressure, albuminuria, hyperlipidaemia
|
1.32 (1.12–1.56) female&
|
Wang et al. [[23]] 2011
|
China
|
Prospective cohort
|
3 years
|
CP
|
>7.0 mg/dL (male); >6.0 mg/dL (female)
|
GFR <60
|
N.R.
|
N.R.
|
1.03 (1.01–1.06)&
|
Age, gender, BMI, smoking, alcohol, exercise, Hypercholesteraemia, education, hyperlipidaemia
|
Jalal et al. [[24]] 2010
|
America
|
Prospective observational study.
|
6 years
|
DP
|
N.R.
|
ACR > 30
|
N.R.
|
N.R.
|
1.80 (1.20-2.80)#
|
Age, gender, BMI, blood pressure, albuminuria, duration of diabetes, HbA1c, serum creatinine, medication for CKD or hyperuricaemia
|
Yen et al. [[25]] 2009
|
Taiwan
|
Prospective cohort
|
32.4 months
|
CP
|
> 6.6 mg/dL
|
eGFR < 60
|
84/312
|
60/488
|
0.997 (0.847–1.175)&
|
Age, gender, BMI, Diabetes, smoking, blood pressure, Hypercholesteraemia, albuminuria, serum creatinine
|
(>65 years old)
|
Weiner et al. [[26]] 2008
|
America
|
Prospective cohort
|
8.5 years
|
CP
|
>7.4 mg/dL (male); >6.1 mg/dl (female)
|
eGFR < 60
|
260/3167
|
481/10171
|
1.07 (1.01–1.14)&
|
Age, gender, race, diabetes, BP, cardiac disease, smoke, alcohol use, education, lipid, albumin
|
Obermayr et al. [[27]] 2008
|
Austria
|
Retrospective cohort
|
7 years
|
CP
|
7.0–8.9 mg/dL
|
eGFR < 60
|
N.R.
|
N.R.
|
1.26 (1.02–1.55)&
|
Age, gender, Diabetes, LDL, hyperlipidaemia, medication for CKD or hyperuricaemia
|
Domrongkitchaiporn et al. [[28]] 2005
|
Thailand
|
Retrospective cohort
|
12 years
|
CP
|
6.30–14.50 mg/dL
|
eGFR <60
|
N.R.
|
N.R.
|
1.82 (1.12–2.98)#
|
BMI, Diabetes, smoking, blood pressure, Hypercholesteraemia, albuminuria
|